These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16205695)

  • 1. Modelling the impact of population-based cytologic screening on cervical cancer incidence and mortality in Hong Kong: an age--period--cohort approach.
    Woo PP; Thach TQ; Choy ST; McGhee SM; Leung GM
    Br J Cancer; 2005 Oct; 93(9):1077-83. PubMed ID: 16205695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of screening on cervical cancer incidence and mortality in New South Wales implied by influences of period of diagnosis and birth cohort.
    Taylor RJ; Morrell SL; Mamoon HA; Wain GV
    J Epidemiol Community Health; 2001 Nov; 55(11):782-8. PubMed ID: 11604432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ; Leung GM; Woo PP; Goldie SJ
    J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-period-cohort analysis of cervical cancer incidence in Hong Kong from 1972 to 2001 using maximum likelihood and Bayesian methods.
    Leung GM; Woo PP; McGhee SM; Cheung AN; Fan S; Mang O; Thach TQ; Ngan HY
    J Epidemiol Community Health; 2006 Aug; 60(8):712-20. PubMed ID: 16840762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.
    Shi JF; Canfell K; Lew JB; Zhao FH; Legood R; Ning Y; Simonella L; Ma L; Kang YJ; Zhang YZ; Smith MA; Chen JF; Feng XX; Qiao YL
    BMC Cancer; 2011 Jun; 11():239. PubMed ID: 21668946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensified screening among high risk women within the organised screening programme for cervical cancer in Finland.
    Kotaniemi-Talonen L; Malila N; Anttila A; Nieminen P; Hakama M
    Acta Oncol; 2011 Jan; 50(1):106-11. PubMed ID: 20560860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring and evaluation of a model demonstration project for the control of cervical cancer in Nakhon Phanom province, Thailand.
    Deerasamee S; Srivatanakul P; Sriplung H; Nilvachararung S; Tansuwan U; Pitakpraiwan P; Kaewkungwal J; Singhasivanon P; Nimnakorn P; Sankaranarayanan R
    Asian Pac J Cancer Prev; 2007; 8(4):547-56. PubMed ID: 18260727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer prevention through cytologic and human papillomavirus DNA screening in Hong Kong Chinese women.
    Wu J
    Hong Kong Med J; 2011 Jun; 17(3 Suppl 3):20-4. PubMed ID: 21673355
    [No Abstract]   [Full Text] [Related]  

  • 10. The challenges of organising cervical screening programmes in the 15 old member states of the European Union.
    Arbyn M; Rebolj M; De Kok IM; Fender M; Becker N; O'Reilly M; Andrae B
    Eur J Cancer; 2009 Oct; 45(15):2671-8. PubMed ID: 19695867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
    Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
    J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
    Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
    Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening.
    Adab P; McGhee SM; Yanova J; Wong CM; Hedley AJ
    Med Care; 2004 Jun; 42(6):600-9. PubMed ID: 15167328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
    Goldie SJ; Kuhn L; Denny L; Pollack A; Wright TC
    JAMA; 2001 Jun; 285(24):3107-15. PubMed ID: 11427139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who receives, benefits from and is harmed by cervical and breast cancer screening among Hong Kong Chinese?
    Leung GM; Woo PP; Cowling BJ; Tsang CS; Cheung AN; Ngan HY; Galbraith K; Lam TH
    J Public Health (Oxf); 2008 Sep; 30(3):282-92. PubMed ID: 18482996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
    Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
    Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical cancer screening programme in Finland with an example on implementing alternative screening methods.
    Anttila A; Nieminen P
    Coll Antropol; 2007 Apr; 31 Suppl 2():17-22. PubMed ID: 17600933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for cervical abnormalities among Hong Kong Chinese women: a large-scale community-based cervical screening program.
    Wong HY; Loke AY; Chan NH
    J Womens Health (Larchmt); 2011 Jan; 20(1):53-9. PubMed ID: 21091197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.